Herein, we aimed to identify the landscape of ROS1 gene fusions in Chinese NSCLC patients as well as examine the therapeutic efficacy of crizotinib in patients with different ROS1 fusion partners. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.